



IFW

MAIL STOP - PCT  
Docket No. 27252U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:	ULRICH	Art Unit:	XXXX
Appl. No.:	10/573,525	Examiner:	XXXX
Filing Date:	March 24, 2006	Conf. No.:	XXXX
Intl. Appl. No.:	PCT/EP04/52376		
Intl. Filing Date:	September 30, 2004		
Title:	IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS		

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

1. Second Information Disclosure Statement;
2. Second PTO Form-1449 with nineteen (19) references cited; and
3. Copies of the eighteen (18) of nineteen (19) references cited.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,  
THE NATH LAW GROUP

JUN 1, 2007  
THE NATH LAW GROUP  
112 S. West St.  
Alexandria, VA 22314  
GMN/SMM/le

  
\_\_\_\_\_  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375



MAIL STOP - PCT  
Docket No. 27252U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:	ULRICH	Art Unit:	XXXX
Appl. No.:	10/573,525	Examiner:	XXXX
Filing Date:	March 24, 2006	Conf. No.:	XXXX
Intl. Appl. No.:	PCT/EP04/52376		
Intl. Filing Date:	September 30, 2004		
Title:	IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTASE INHIBITORS		

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

A Second Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- a. ☒ [XXX] The enclosed second statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- b. ☐ [ ] The enclosed second statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.  
The enclosed second statement is accompanied by [check one]:  
☐ [ ] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or  
☐ [ ] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- c. ☐ [ ] The enclosed second statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

- ☐ Certification report(e) below; and  
☐ a check in the amount as required by 1.17(p).

d. ☐ The enclosed second statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed second Information Disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this second statement,

☐ I hereby certify or that no item of information in the enclosed second Information Disclosure statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this second Information Disclosure statement.

☐ Appropriate certification is attached. or

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XXX] Copies of the documents are attached herewith with a completed PTO Form-1449.

☐ Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or  
[XXX] Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.


**MAIL STOP - PCT**  
**Docket No. 27252U**


The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.


Respectfully submitted,  
**THE NATH LAW GROUP**

June 1, 2007  
**THE NATH LAW GROUP**  
112 S. West St.  
Alexandria, VA 22314  
GMN/SMM/le

  
\_\_\_\_\_  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

<b>SECOND PTO FORM-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>		Inventor: ULRICH		Art Unit: XXXX	
		Appl. No.: 10/573,525		Examiner: XXXX	
		Filing Date: 3/24/2006		Conf. No: XXXX	
 <b>U.S. PATENT DOCUMENTS</b>					
Exam. Initial		No.	Issue/Public. Date	Inventor	Filed Date
	A1	7,138,399 (corresponds to WO03/080607)	11/21/2006	Ulrich	3/25/2003
<b>FOREIGN PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Public. Date	Country	Translation
	A2	2005/061496 A1	7/7/2005	WO	N/A
	A3	2005/030771 A1	4/7/2005	WO	N/A
	A4	2005/030770 A1	4/7/2005	WO	N/A
	A5	2005/030768 A1	4/7/2005	WO	N/A
	A6	97/25030 A1	7/17/1997	WO	N/A
	A7	03/080607 A1	10/2/2003	WO	N/A
<b>OTHER</b>					
Exam. Initial					
	A8	Hua, L.L., et al., "Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNF $\alpha$ expression in human fetal astrocytes", <u>Journal of Neuroimmunology</u> , Vol. 126, Pgs. 180-189, (2002).			
	A9	Kim, M-S, et al., "Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid $\beta$ peptide and interleukin-1 $\beta$ ", <u>Neuroscience Letters</u> , Vol. 321, Pgs. 105-109, (2002).			
	A10	D'Agostino, P., et al., "Tetracycline inhibits the nitric oxide synthase activity induced by endotoxin in cultured murine macrophages", <u>European Journal of Pharmacology</u> , Vol. 346, Pgs. 283-290, (1998).			
	A11	Kiss, J., et al., "Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats", <u>European Journal of Pharmacology</u> , Vol. 336, Pgs. 219-224, (1997).			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

	<p>A12 Sautebin, L., "Prostaglandins and nitric oxide as molecular targets for anti-inflammatory therapy", <u>Fitoterapia</u>, Vol. 71, Pgs. S48-S57, (2000).</p> <p>A13 Ohtsuka, M., et al., "PPA250 [3-(2,4-Difluorophenyl)-6-(2-[4-(1H-imidazol-1-ylmethyl)Phenoxy]ethoxy)-2-phenylpyridine], a Novel Orally Effective Inhibitor of the Dimerization of Inducible Nitric-Oxide Synthase, Exhibits an Anti-Inflammatory Effect in Animal Models of Chronic Arthritis", <u>The Journal of Pharmacology and Experimental Therapeutics</u>, Vol. 303, No. 1, Pgs. 52-57, (2002).</p>
	<p>A14 Hansel, T. T., et al., "A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics", <u>FASEB J</u>, Vol. 17, Pgs. 1298-1300, (2003).</p>
	<p>A15 Tinker, A. C., et al., "1,2-Dihydro-4-quinazolinamines: Potent, Highly Selective Inhibitors of Inducible Nitric Oxide Synthase Which Show Antiinflammatory Activity in Vivo", <u>J. Med. Chem.</u>, Vol. 46, Pgs. 913-916, (2003).</p>
	<p>A16 Kankuri, E., et al., "Suppression of Acute Experimental Colitis by a Highly Selective Inducible Nitric-Oxide Synthase Inhibitor, N-[3-(Aminomethyl)benzyl]acetamidine", <u>The Journal of Pharmacology and Experimental Therapeutics</u>, Vol. 298, No. 3, Pgs. 1128-1132, (2001).</p>
	<p>A17 Liu, Z-Q, et al., "Specificity of inducible nitric-oxide synthase inhibitors: prospects for their clinical therapy", <u>Acta Pharmacol Sin</u>, Vol. 20, No. 11, Pgs. 1052-1056, (1999).</p>
	<p>A18 Salvemini, D., et al., "Dual Inhibition of Nitric Oxide and Prostaglandin Production Contributes to the Antiinflammatory Properties of Nitric Oxide Synthase Inhibitors", <u>J. Clin. Invest.</u>, Vol. 96, Pgs. 301-308, (1995).</p>
	<p>A19 Cuzzocrea, S., et al., "Beneficial effects of GW274150, a novel, potent and selective inhibitor of INOS activity, in a rodent model of collagen-induced arthritis", <u>European Journal of Pharmacology</u>, Vol. 453, Pgs. 119-129, (2002).</p>

Examiner

/Nilofar Rahmani/

Date Considered

05/28/2008

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/